Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
FEUERECKER Benedikt;
KNORR Karina;
BEHESHTI A;
SEIDL C.;
D'ALESSANDRIA C;
BRUCHERTSEIFER Frank;
TAUBER R;
RETZ M;
WEBER Wolfgang;
MORGENSTERN Alfred;
EIBER Matthias;
2019-04-11
SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
JRC113791
0029-5566 (online),
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0039-1683483,
https://publications.jrc.ec.europa.eu/repository/handle/JRC113791,
10.1055/s-0039-1683483 (online),
Additional supporting files
| File name | Description | File type | |
|---|
